BioSpace News Archive

Relay Therapeutics, Inc. is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on Wednesday, February 9, 2022 at 9:30 a.m. ET and a panel at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. ET on Tumor Agnostic Development.

Phase 2/3 trial data, the basis for submission, demonstrates Rylaze maintains a clinically meaningful level of nadir serum asparaginase activity throughout the entire duration of treatment for adult and pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma.

AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2021.

Bluejay Therapeutics today announced that Nancy Shulman, M.D., joined Bluejay as chief medical officer, bringing over 20 years of clinical development experience with her to Bluejay Therapeutics.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company will be participating in the Guggenheim Oncology Conference taking place virtually February 9, 2022, through February 11, 2022.

A hemodialysis bloodline system is a type of tubing system that connects a patient’s blood circulation to a dialyzer in the course of the dialysis treatment.

Conjugated polymer nanoparticles (CPN) are fluorescence emitting entities that are utilized in bio imaging, research & development, and photo optics.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global prosthetic liners market is expected to develop at a CAGR of 4.5% from 2021 to 2031.

Balantidiasis, also known as Balantidium coli infection, is a disorder caused by Balantidium coli, an intestinal protozoan parasite. The parasite is transmitted through the fecal-oral route.

NorthSea Therapeutics B.V., a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, announces it has initiated a Phase 1 study with SEFA-6179 in adult subjects, targeting the initial orphan indication of the treatment of IFALD.